HSBC Holdings
ZNTL icon

HSBC Holdings’s Zentalis Pharmaceuticals ZNTL Stock Holding History

HSBC Holdings’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-27,877
Closed -$33.3K – 3209
2025
Q2 		$33.3K Buy
+27,877
New +$36.8K ﹤0.01% 2959

Other funds holding ZNTL

MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

HSBC Holdings's ZNTL Position: Q3 2025 in Review

HSBC Holdings sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2025, closing a stake of 27,877 shares — an estimated $33.3K sold.

HSBC Holdings first reported a position in ZNTL in Q2 2025 and held it in 1 quarter. The position peaked at $33.3K in Q2 2025. 99 funds tracked by Wall St. Rank hold ZNTL as of Q3 2025.

  • HSBC Holdings reported no remaining Zentalis Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • HSBC Holdings sold 27,877 Zentalis Pharmaceuticals shares in Q3 2025, an estimated $33.3K.
  • HSBC Holdings first reported a position in Zentalis Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • HSBC Holdings's Zentalis Pharmaceuticals position peaked at $33.3K in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.